Meghan Joyce Sells 10,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Meghan Joyce sold 10,000 shares of Guardant Health stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the completion of the sale, the director directly owned 11,183 shares of the company’s stock, valued at approximately $1,420,017.34. The trade was a 47.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Trading Up 4.7%

Guardant Health stock traded up $6.03 on Thursday, reaching $133.06. 2,014,204 shares of the stock were exchanged, compared to its average volume of 2,128,095. The stock has a market cap of $17.64 billion, a PE ratio of -39.25 and a beta of 1.61. Guardant Health, Inc. has a twelve month low of $40.35 and a twelve month high of $134.28. The firm has a fifty day moving average price of $97.62 and a two-hundred day moving average price of $100.64.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of research analyst reports. BTIG Research set a $160.00 target price on shares of Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, May 27th. Raymond James Financial reissued an “outperform” rating and set a $129.00 target price on shares of Guardant Health in a research report on Monday, February 23rd. Citigroup boosted their target price on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Guggenheim lowered shares of Guardant Health from a “buy” rating to a “buy” rating in a research report on Thursday, May 28th. Finally, Evercore raised shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 target price for the company in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and a consensus target price of $136.37.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GH. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at about $27,000. Chesapeake Asset Management LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Guardant Health during the fourth quarter valued at about $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at about $35,000. Finally, Parallel Advisors LLC raised its position in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.